Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 7304658, 8 pages
https://doi.org/10.1155/2017/7304658
Research Article

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

1Institute of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
2Department of Mathematics, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
34th Department of Internal Medicine-Haematology, Faculty of Medicine, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
4Department of Clinical Immunology and Allergy, Faculty of Medicine, Masaryk University, St. Anne‘s University Hospital, Brno, Czech Republic
5RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic

Correspondence should be addressed to P. Kralickova; zc.khnf@avokcilark.anilvap

Received 18 April 2017; Revised 27 July 2017; Accepted 7 September 2017; Published 17 December 2017

Academic Editor: Senthami R. Selvan

Copyright © 2017 P. Kralickova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Scarfo, A. J. Ferreri, and P. Ghia, “Chronic lymphocytic leukaemia,” Critical Reviews in Oncology/Hematology, vol. 104, pp. 169–182, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Van Bockstaele, B. Verhasselt, and J. Philippé, “Prognostic markers in chronic lymphocytic leukemia: a comprehensive review,” Blood Reviews, vol. 23, no. 1, pp. 25–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. A. Dasanu and D. T. Alexandrescu, “Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia,” Medscape General Medicine, vol. 9, no. 4, p. 35, 2007. View at Google Scholar
  4. S. Molica, “Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment,” Leukemia & Lymphoma, vol. 13, no. 3-4, pp. 203–214, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Oscier, C. Dearden, E. Eren et al., “Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 159, no. 5, pp. 541–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. D. Hamblin and T. J. Hamblin, “The immunodeficiency of chronic lymphocytic leukaemia,” British Medical Bulletin, vol. 87, pp. 49–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Ravandi and S. O'Brien, “Immune defects in patients with chronic lymphocytic leukemia,” Cancer Immunology, Immunotherapy, vol. 55, no. 2, pp. 197–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Dearden, “Disease-specific complications of chronic lymphocytic leukemia,” Hematology. American Society of Hematology. Education Program, vol. 2008, pp. 450–456, 2008. View at Publisher · View at Google Scholar
  9. V. Friman, O. Winqvist, C. Blimark, P. Langerbeins, H. Chapel, and F. Dhalla, “Secondary immunodeficiency in lymphoproliferative malignancies,” Hematological Oncology, vol. 34, no. 3, pp. 121–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Sanchez-Ramon, F. Dhalla, and H. Chapel, “Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy,” Frontiers in Immunology, vol. 7, p. 317, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Jolles, H. Chapel, and J. Litzman, “When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach,” Clinical and Experimental Immunology, vol. 188, no. 3, pp. 333–341, 2017. View at Publisher · View at Google Scholar
  12. F. A. Bonilla, I. Barlan, H. Chapel et al., “International Consensus Document (ICON): common variable immunodeficiency disorders,” The Journal of Allergy and Clinical Immunology. In Practice, vol. 4, no. 1, pp. 38–59, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. E. S. Resnick, E. L. Moshier, J. H. Godbold, and C. Cunningham-Rundles, “Morbidity and mortality in common variable immune deficiency over 4 decades,” Blood, vol. 119, no. 7, pp. 1650–1657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Gathmann, N. Mahlaoui, CEREDIH et al., “Clinical picture and treatment of 2212 patients with common variable immunodeficiency,” The Journal of Allergy and Clinical Immunology, vol. 134, no. 1, pp. 116–126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. U. Galili, “Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits,” Immunology, vol. 140, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Saleh, S. Embry, A. Nauli, S. Atyia, and G. Krishnaswamy, “Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution,” Clinical and Molecular Allergy, vol. 10, no. 1, p. 5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. C. H. Chung, B. Mirakhur, E. Chan et al., “Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1109–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hamanova, M. Chmelikova, I. Nentwich, V. Thon, and J. Lokaj, “Anti-Gal IgM, IgA and IgG natural antibodies in childhood,” Immunology Letters, vol. 164, no. 1, pp. 40–43, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Bernth-Jensen, B. K. Moller, J. C. Jensenius, and S. Thiel, “Biological variation of anti-alpha Gal-antibodies studied by a novel time-resolved immunofluorometric assay,” Journal of Immunological Methods, vol. 373, no. 1-2, pp. 26–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. E. Conley, L. D. Notarangelo, and A. Etzioni, “Diagnostic criteria for primary immunodeficiencies. representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies),” Clinical Immunology, vol. 93, no. 3, pp. 190–197, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Parikh, J. F. Leis, K. G. Chaffee et al., “Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes,” Cancer, vol. 121, no. 17, pp. 2883–2891, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Visentin, N. Compagno, F. Cinetto et al., “Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy,” Haematologica, vol. 100, no. 12, pp. e515–e518, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Griffiths, J. Lea, C. Bunch, M. Lee, and H. Chapel, “Predictors of infection in chronic lymphocytic leukaemia (CLL),” Clinical and Experimental Immunology, vol. 89, no. 3, pp. 374–377, 1992. View at Publisher · View at Google Scholar
  24. I. Ben-Bassat, A. Many, M. Modan, C. Peretz, and B. Ramot, “Serum immunoglobulins in chronic lymphocytic leukemia,” The American Journal of the Medical Sciences, vol. 278, no. 1, pp. 4–9, 1979. View at Publisher · View at Google Scholar
  25. V. A. Morrison, “Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches,” Best Practice & Research. Clinical Haematology, vol. 23, pp. 145–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. Andersen, F. J. Vojdeman, M. K. Andersen et al., “Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death,” Leukemia & Lymphoma, vol. 57, no. 7, pp. 1592–1599, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Shvidel, T. Tadmor, A. Braester et al., “Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL study group,” European Journal of Haematology, vol. 93, no. 1, pp. 29–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Pasiarski, J. Rolinski, E. Grywalska et al., “Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients – preliminary report,” PLoS One, vol. 9, no. 12, article e114966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Rozman, E. Montserrat, and N. Viñolas, “Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance,” Cancer, vol. 61, no. 2, pp. 279–283, 1988. View at Google Scholar
  30. P. D. Wadhwa and V. A. Morrison, “Infectious complications of chronic lymphocytic leukemia,” Seminars in Oncology, vol. 33, pp. 240–249, 2006. View at Google Scholar
  31. I. Quinti, A. Soresina, A. Guerra et al., “Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study,” Journal of Clinical Immunology, vol. 31, no. 3, pp. 315–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. F. M. Cavaliere, C. Milito, H. Martini et al., “Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency,” Journal of Clinical Immunology, vol. 33, no. 4, pp. 838–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Freeman, K. R. Crassini, O. G. Best et al., “Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 54, no. 1, pp. 99–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Svensson, M. Hoglund, and H. Cherif, “Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia,” Scandinavian Journal of Infectious Diseases, vol. 45, pp. 537–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Nosari, “Infectious complications in chronic lymphocytic leukemia,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, article e2012070, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Sinisalo, J. Aittoniemi, P. Oivanen, H. Käyhty, R. M. Olander, and J. Vilpo, “Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 114, no. 1, pp. 107–110, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Hartkamp, A. H. Mulder, G. T. Rijkers, H. van Velzen-Blad, and D. H. Biesma, “Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia,” Vaccine, vol. 19, no. 13-14, pp. 1671–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Sinisalo, J. Vilpo, M. Itälä, M. Väkeväinen, J. Taurio, and J. Aittoniemi, “Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia,” Vaccine, vol. 26, no. 1, pp. 82–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Parker, K. Lundberg-Swanson, Z. E. Holzknecht et al., “Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies,” Human Immunology, vol. 45, no. 2, pp. 94–104, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Chovancova, M. Vlkova, J. Litzman, J. Litzman, J. Lokaj, and V. Thon, “Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination,” Vaccine, vol. 29, no. 24, pp. 4142–4150, 2011. View at Google Scholar